The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors.
Emiliano Calvo
No relevant relationships to disclose
Karim Adnane Benhadji
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Analia Azaro
No relevant relationships to disclose
Ignacio Duran
No relevant relationships to disclose
Guillem Argiles
No relevant relationships to disclose
Valentina Boni
No relevant relationships to disclose
Ute Ohnmacht
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Johan Wallin
Employment or Leadership Position - Lilly
William Mark Bumgardner
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Jordi Rodon Ahnert
Consultant or Advisory Role - Lilly